Viewing Study NCT00004695



Ignite Creation Date: 2024-05-05 @ 11:19 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004695
Status: COMPLETED
Last Update Posted: 2015-03-25
First Post: 2000-02-24

Brief Title: Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency
Sponsor: Icahn School of Medicine at Mount Sinai
Organization: FDA Office of Orphan Products Development

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 1999-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES I Determine whether polyethylene-glycol-conjugated interleukin 2 PEG-IL-2 can reduce the number of infections in patients with common variable immunodeficiency

II Determine whether this therapy can improve lung functions in these patients with pulmonary impairment
Detailed Description: PROTOCOL OUTLINE This is a randomized open-label study Patients are randomized to receive polyethylene-glycol-conjugated interleukin 2 PEG-IL-2 or placebo

Patients receive PEG-IL-2 or placebo by subcutaneous injection weekly for 18 months Patients maintain a daily diary for 24 months

Patients are followed every 4 months for 2 years

Completion date provided represents the completion date of the grant per OOPD records

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
MTS-FDR001162 None None None
MTS-93-726-ME None None None